{
    "root": "30b10990-92c4-531b-e063-6294a90a7a27",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Darunavir",
    "value": "20250319",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE (35 .MU.M)",
            "code": "40UAA97IT9"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY)",
            "code": "GRV5BG8C5N"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "DARUNAVIR",
            "code": "YO603Y8113",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_367163"
        }
    ],
    "indications": {
        "text": "darunavir tablets , co-administered ritonavir ( darunavir tablets/ritonavir ) , combination antiretroviral agents , indicated treatment human immunodeficiency virus ( hiv-1 ) infection adult pediatric patients 3 years age older [ ( 8.4 ) ( 14 ) ] .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "immunodeficiency",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_101997"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 testing : treatment-experienced patients , treatment history genotypic and/or phenotypic testing recommended prior initiation therapy darunavir tablets/ritonavir assess susceptibility hiv-1 virus ( 2.1 , 12.4 ) monitor serum liver chemistry tests therapy darunavir tablets/ritonavir . ( 2.1 , 2.2 , 5.2 ) \u2022 treatment-na\u00efve adult patients treatment-experienced adult patients darunavir resistance associated substitutions : 800 mg ( one 800 mg tablet ) taken ritonavir 100 mg daily food . ( 2.3 ) \u2022 treatment-experienced adult patients least one darunavir resistance associated substitution : 600 mg ( one 600 mg tablet ) taken ritonavir 100 mg twice daily food . ( 2.3 ) \u2022 pregnant patients : 600 mg ( one 600 mg tablet ) taken ritonavir 100 mg twice daily food . ( 2.4 ) \u2022 pediatric patients ( 3 less 18 years age weighing least 10 kg ) : darunavir tablets ritonavir based body weight exceed adult dose . darunavir tablets taken ritonavir food . ( 2.5 ) \u2022 darunavir tablets/ritonavir recommended patients severe hepatic impairment . ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "darunavir 600 mg tablets available yellow , oval shaped , biconvex , film-coated tablets debossed ' v ' one side ' 5 ' side . 600 mg tablet contains darunavir amorphous equivalent 600 mg darunavir . bottles 60 ndc 31722-088-60 darunavir 800 mg tablets available yellow , oval shaped , biconvex , film-coated tablets debossed ' v ' one side ' 7 ' side . 800 mg tablet contains darunavir amorphous equivalent 800 mg darunavir bottles 30 ndc 31722-089-30 storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep darunavir tablets reach children .",
    "adverseReactions": "co-administration darunavir tablets/ritonavir contraindicated drugs highly dependent cyp3a clearance elevated plasma concentrations associated serious and/or life-threatening events ( narrow therapeutic index ) . drugs contraindicated drugs ( may lead reduced efficacy darunavir ) listed [ ( 7.3 ) ] . due need co-administration darunavir tablets ritonavir , please refer ritonavir prescribing information description ritonavir . \u2022 alpha 1-adrenoreceptor antagonist : alfuzosin \u2022 anti-gout : colchicine , patients renal and/or hepatic impairment \u2022 antimycobacterial : rifampin \u2022 antipsychotics : lurasidone , pimozide \u2022 cardiac disorders : dronedarone , ivabradine , ranolazine \u2022 ergot derivatives , e.g . dihydroergotamine , ergotamine , methylergonovine \u2022 herbal product : st. john \u2019 wort ( hypericum perforatum ) \u2022 hepatitis c direct acting antiviral : elbasvir/grazoprevir \u2022 lipid modifying agents : lomitapide , lovastatin , simvastatin \u2022 opioid antagonist : naloxegol \u2022 pde-5 inhibitor : sildenafil used treatment pulmonary arterial hypertension \u2022 sedatives/hypnotics : orally administered midazolam , triazolam",
    "indications_original": "Darunavir tablets, co-administered with ritonavir (darunavir tablets/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older\n \n  \u00a0[see Use in Specific Populations\n  \n   (8.4)\u00a0and Clinical Studies\n  \n   (14)].",
    "contraindications_original": "\u2022\u00a0 Testing: o\u00a0In treatment-experienced patients, treatment history genotypic and/or phenotypic testing is recommended prior to initiation of therapy with\u00a0darunavir tablets/ritonavir to assess drug susceptibility of the HIV-1 virus ( 2.1, 12.4) o\u00a0 Monitor serum liver chemistry tests before and during therapy with\u00a0 darunavir tablets/ritonavir. ( 2.1, 2.2 , 5.2) \u2022\u00a0Treatment-na\u00efve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet) taken with ritonavir 100 mg once daily and with food. (2.3) \u2022\u00a0Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. (2.3) \u2022\u00a0Pregnant patients: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. (2.4) \u2022\u00a0Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of darunavir tablets and ritonavir is based on body weight and should not exceed the adult dose.\u00a0 Darunavir tablets should be taken with ritonavir and with food. (2.5) \u2022\u00a0Darunavir tablets/ritonavir is not recommended for use in patients with severe hepatic impairment. (2.6)",
    "warningsAndPrecautions_original": "Darunavir 600 mg tablets are available as yellow, oval shaped, biconvex, film-coated tablets debossed with 'V' on one side and '5' on the other side. Each 600 mg tablet contains darunavir amorphous equivalent 600 mg of darunavir. \n    Bottles of 60\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-088-60\n \n                  \n                  \n                  Darunavir 800 mg tablets are available as yellow, oval shaped, biconvex, film-coated tablets debossed with 'V' on one side and '7' on the other side. Each 800 mg tablet contains darunavir amorphous equivalent 800 mg of darunavir \n    Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 31722-089-30 \n  \n                     \n                     Storage\n                       Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); with excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. \n  \n                       Keep darunavir tablets out of reach of children.",
    "adverseReactions_original": "Co-administration of darunavir tablets/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below\n \n  [see Drug Interactions\n  \n   (7.3)].\u00a0\n \n  Due to the need for co-administration of darunavir tablets with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications.\u00a0\n\n \n                  \u2022\u00a0Alpha 1-adrenoreceptor antagonist: alfuzosin \n    \u2022\u00a0Anti-gout: colchicine, in patients with renal and/or hepatic impairment \n    \u2022\u00a0Antimycobacterial: rifampin \n    \u2022\u00a0Antipsychotics: lurasidone, pimozide \n    \u2022\u00a0Cardiac Disorders: dronedarone, ivabradine, ranolazine \n    \u2022\u00a0Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine\u00a0 \n    \u2022\u00a0Herbal product: St. John\u2019s wort\n \n  (Hypericum perforatum)\n                       \u2022\u00a0Hepatitis C direct acting antiviral: elbasvir/grazoprevir \n    \u2022\u00a0Lipid modifying agents: lomitapide, lovastatin, simvastatin \n    \u2022\u00a0Opioid Antagonist: naloxegol \n    \u2022\u00a0PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension \n    \u2022\u00a0Sedatives/hypnotics: orally administered midazolam, triazolam",
    "drug": [
        {
            "name": "Darunavir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_367163"
        }
    ]
}